Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

JAMA
April 20, 2021, Vol 325, No. 15, Pages 1489-1575
https://jamanetwork.com/journals/jama/currentissue

 

Original Investigation
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Kathryn E. Stephenson, MD, MPH; Mathieu Le Gars, PhD; Jerald Sadoff, MD; et al.
free access has active quiz
JAMA. 2021;325(15):1535-1544. doi:10.1001/jama.2021.3645
This randomized trial compares the immunogenicity of a SARS-CoV-2 Ad26.COV2.S vaccine at high vs low vs no dose (placebo) in humans, including the kinetics, magnitude, and phenotype of coronavirus spike-specific humoral and cellular immune responses.